| abstract |
The present disclosure generally describes eukaryotic initiation factor 2B modulators, or pharmaceutically acceptable salts thereof, stereoisomers, mixtures of stereoisomers, or prodrugs, and the manufacture and use thereof. Regarding the method. [Selection diagram] None |